Diodes Incorporated reports Q1 2026 results on May 11 with the stock running well ahead of where analysts expected it to be — and Wall Street scrambling to catch up.
The analyst angle here is the real story. Truist Securities upgraded DIOD from Hold to Buy on April 13, lifting its target from $67 to $98. Then, just yesterday, Truist raised that target again — to $139 — while maintaining the Buy rating. The stock is now at $111.41, sitting between those two goalposts. Baird also nudged its Outperform target higher in early April, from $80 to $100. That means the two most active covering firms have both turned more constructive in the month leading into the print, even as the stock has already surged 52% over the past month.
The bull case rests on product-mix improvement and broadening exposure across automotive, industrial, and computing markets. Bears, meanwhile, point to the early-cycle nature of the recovery — noting that while revenue trends are moving in the right direction, the company's longer-term targets (including $1B in gross profit) still depend on either further execution or an additional acquisition to be achievable within a realistic timeframe. On consensus data, only one Buy rating is formally recorded with a mean target of $99 — meaning the stock has already run through that figure. The Truist revision to $139 reflects a fresh re-rating that hasn't yet filtered into consensus, but it does suggest at least one bellwether firm believes the market is still underestimating earnings power.
Options positioning tells a more relaxed story. The put/call ratio is running at 0.48, well below its 20-day average of 0.55 — and near the lower end of its recent range. That reads as call-side appetite rather than defensive hedging into the print, consistent with the momentum the stock has built. Short sellers are not pressing the bet: SI sits at just 3.2% of free float, down more than 21% over the past month as the rally has compressed short positions. Availability in the borrow market is ample, cost to borrow has eased 16% over the past week to a negligible 0.375% annualised, and the ORTEX short score of 34 ranks only in the 55th percentile — none of this points to meaningful squeeze risk or aggressive short conviction.
The one counterweight worth noting is insider activity. In February, Chairman Keh Shew Lu sold over 111,000 shares for roughly $7.5 million combined, and both the CEO and CFO trimmed positions around the same time. Those sales occurred at prices near $67–$71 — well below Friday's close — which gives them limited predictive weight at current levels, but they do reflect a cluster of insider distribution that preceded the rally rather than participated in it. Among institutional holders, Victory Capital added 458,727 shares as recently as April, providing a visible counterpoint to that selling pattern.
The May 11 print is therefore less about whether a recovery is underway and more about whether the scale and pace of that recovery justifies a stock that has already re-rated dramatically ahead of confirmed numbers.
See the live data behind this article on ORTEX.
Open DIOD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
